Do analysts prefer SXTC or LRMR?

Larimar Therapeutics has a consensus price target of $12.71, suggesting a potential upside of 241.78%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09

Which has stronger earnings and valuation, SXTC or LRMR?

China SXT Pharmaceuticals has higher revenue and earnings than Larimar Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 80.80 -$6.20M N/A N/A Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A

Is SXTC or LRMR more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A Larimar Therapeutics N/A -134.14% -96.00%

Does the media refer more to SXTC or LRMR?

In the previous week, Larimar Therapeutics had 5 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 8 mentions for Larimar Therapeutics and 3 mentions for China SXT Pharmaceuticals. Larimar Therapeutics' average media sentiment score of 1.07 beat China SXT Pharmaceuticals' score of 0.96 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SXTC or XFOR?

X4 Pharmaceuticals has a consensus target price of $9.70, suggesting a potential upside of 141.29%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has better valuation and earnings, SXTC or XFOR?

China SXT Pharmaceuticals has higher earnings, but lower revenue than X4 Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 80.80 -$6.20M N/A N/A X4 Pharmaceuticals $35.11M 10.80 -$79.20M -$4.54 N/A

Does the media refer more to SXTC or XFOR?

In the previous week, X4 Pharmaceuticals had 2 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 3 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat X4 Pharmaceuticals' score of 0.63 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SXTC or FHTX?

Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 112.43%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has higher valuation and earnings, SXTC or FHTX?

China SXT Pharmaceuticals has higher earnings, but lower revenue than Foghorn Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 80.80 -$6.20M N/A N/A Foghorn Therapeutics $30.91M 10.22 -$74.28M -$1.16 N/A

Is SXTC or FHTX more profitable?

China SXT Pharmaceuticals has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A Foghorn Therapeutics -266.88% N/A -35.38%

Does the media favor SXTC or FHTX?

In the previous week, Foghorn Therapeutics had 2 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 5 mentions for Foghorn Therapeutics and 3 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat Foghorn Therapeutics' score of 0.66 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SXTC or ZSQR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, SXTC or ZSQR?

China SXT Pharmaceuticals has higher earnings, but lower revenue than Coeptis Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 80.80 -$6.20M N/A N/A Coeptis Therapeutics $1.36M 211.77 -$11.92M -$2.52 N/A

Do analysts rate SXTC or EDIT?

Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 70.89%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Editas Medicine 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has better valuation and earnings, SXTC or EDIT?

China SXT Pharmaceuticals has higher earnings, but lower revenue than Editas Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 80.80 -$6.20M N/A N/A Editas Medicine $40.52M 7.64 -$160.06M -$1.23 N/A

China SXT Pharmaceuticals (SXTC) Competitors

$2.41 -0.14 (-5.49%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.41 0.00 (-0.04%)

As of 05:32 AM Eastern

Compare

SXTC vs. LRMR, XFOR, FHTX, ZSQR, and EDIT

Should you buy China SXT Pharmaceuticals stock or one of its competitors? MarketBeat compares China SXT Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China SXT Pharmaceuticals include Larimar Therapeutics (LRMR), X4 Pharmaceuticals (XFOR), Foghorn Therapeutics (FHTX), Coeptis Therapeutics (ZSQR), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.

How does China SXT Pharmaceuticals compare to Larimar Therapeutics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Larimar Therapeutics had 5 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 8 mentions for Larimar Therapeutics and 3 mentions for China SXT Pharmaceuticals. Larimar Therapeutics' average media sentiment score of 1.07 beat China SXT Pharmaceuticals' score of 0.96 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China SXT Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Larimar Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a consensus price target of $12.71, suggesting a potential upside of 241.78%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

China SXT Pharmaceuticals has higher revenue and earnings than Larimar Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	80.80	-$6.20M	N/A	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

China SXT Pharmaceuticals has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

China SXT Pharmaceuticals' return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Larimar Therapeutics	N/A	-134.14%	-96.00%

Summary

Larimar Therapeutics beats China SXT Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to X4 Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

China SXT Pharmaceuticals has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

In the previous week, X4 Pharmaceuticals had 2 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 3 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat X4 Pharmaceuticals' score of 0.63 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China SXT Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

X4 Pharmaceuticals has a consensus target price of $9.70, suggesting a potential upside of 141.29%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

China SXT Pharmaceuticals has higher earnings, but lower revenue than X4 Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	80.80	-$6.20M	N/A	N/A
X4 Pharmaceuticals	$35.11M	10.80	-$79.20M	-$4.54	N/A

China SXT Pharmaceuticals has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. China SXT Pharmaceuticals' return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

China SXT Pharmaceuticals beats X4 Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Foghorn Therapeutics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Foghorn Therapeutics	-266.88%	N/A	-35.38%

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

China SXT Pharmaceuticals has higher earnings, but lower revenue than Foghorn Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	80.80	-$6.20M	N/A	N/A
Foghorn Therapeutics	$30.91M	10.22	-$74.28M	-$1.16	N/A

In the previous week, Foghorn Therapeutics had 2 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 5 mentions for Foghorn Therapeutics and 3 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat Foghorn Therapeutics' score of 0.66 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China SXT Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Foghorn Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 112.43%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

China SXT Pharmaceuticals has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market.

Summary

Foghorn Therapeutics beats China SXT Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Coeptis Therapeutics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

China SXT Pharmaceuticals has higher earnings, but lower revenue than Coeptis Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	80.80	-$6.20M	N/A	N/A
Coeptis Therapeutics	$1.36M	211.77	-$11.92M	-$2.52	N/A

In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.89 beat China SXT Pharmaceuticals' score of 0.96 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
China SXT Pharmaceuticals	Positive
Coeptis Therapeutics	Very Positive

China SXT Pharmaceuticals has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China SXT Pharmaceuticals has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. China SXT Pharmaceuticals' return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

China SXT Pharmaceuticals beats Coeptis Therapeutics on 6 of the 11 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Editas Medicine?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 70.89%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

China SXT Pharmaceuticals has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. China SXT Pharmaceuticals' return on equity of 0.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Editas Medicine	-281.59%	-677.39%	-58.25%

China SXT Pharmaceuticals has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market.

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

China SXT Pharmaceuticals has higher earnings, but lower revenue than Editas Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	80.80	-$6.20M	N/A	N/A
Editas Medicine	$40.52M	7.64	-$160.06M	-$1.23	N/A

In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for Editas Medicine. China SXT Pharmaceuticals' average media sentiment score of 0.96 beat Editas Medicine's score of 0.94 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
China SXT Pharmaceuticals	Positive
Editas Medicine	Positive

Summary

China SXT Pharmaceuticals beats Editas Medicine on 8 of the 14 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTC vs. The Competition

Export

Metric	China SXT Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$97.46M	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	N/A	18.77	26.94	24.38
Price / Sales	80.80	344.35	521.23	91.92
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	0.08	4.20	10.89	6.33
Net Income	-$6.20M	$65.13M	$3.59B	$331.02M
7 Day Performance	-5.49%	-2.63%	-1.53%	-0.33%
1 Month Performance	2.55%	2.14%	2.72%	-1.29%
1 Year Performance	-99.04%	23.26%	28.47%	21.30%

China SXT Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTC China SXT Pharmaceuticals	1.0232 of 5 stars	$2.41 -5.5%	N/A	-99.0%	$97.46M	$1.14M	N/A	90	News Coverage Short Interest Decrease
LRMR Larimar Therapeutics	4.3506 of 5 stars	$3.61 +5.9%	$12.71 +252.2%	+7.8%	$375.01M	N/A	N/A	30	Positive News
XFOR X4 Pharmaceuticals	2.9535 of 5 stars	$3.96 +0.5%	$9.38 +136.7%	+171.6%	$373.51M	$9.01M	N/A	80
FHTX Foghorn Therapeutics	2.7695 of 5 stars	$6.17 +2.8%	$11.43 +85.2%	-8.5%	$362.24M	$30.91M	N/A	120	News Coverage Analyst Downgrade High Trading Volume
ZSQR Coeptis Therapeutics	0.3636 of 5 stars	$7.04 -17.1%	N/A	-43.4%	$362.07M	N/A	N/A	2	Positive News Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTC) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China SXT Pharmaceuticals (SXTC) Competitors

SXTC vs. LRMR, XFOR, FHTX, ZSQR, and EDIT

How does China SXT Pharmaceuticals compare to Larimar Therapeutics?

Summary

How does China SXT Pharmaceuticals compare to X4 Pharmaceuticals?

Summary

How does China SXT Pharmaceuticals compare to Foghorn Therapeutics?

Summary

How does China SXT Pharmaceuticals compare to Coeptis Therapeutics?

Summary

How does China SXT Pharmaceuticals compare to Editas Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC vs. The Competition

China SXT Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China SXT Pharmaceuticals (SXTC) Competitors

SXTC vs. LRMR, XFOR, FHTX, ZSQR, and EDIT

How does China SXT Pharmaceuticals compare to Larimar Therapeutics?

Do institutionals and insiders hold more shares of SXTC or LRMR?

Does the media refer more to SXTC or LRMR?

Do analysts prefer SXTC or LRMR?

Which has stronger earnings and valuation, SXTC or LRMR?

Which has more risk and volatility, SXTC or LRMR?

Is SXTC or LRMR more profitable?

Summary

How does China SXT Pharmaceuticals compare to X4 Pharmaceuticals?

Which has more volatility and risk, SXTC or XFOR?

Does the media refer more to SXTC or XFOR?

Do analysts prefer SXTC or XFOR?

Which has better valuation and earnings, SXTC or XFOR?

Is SXTC or XFOR more profitable?

Do institutionals & insiders hold more shares of SXTC or XFOR?

Summary

How does China SXT Pharmaceuticals compare to Foghorn Therapeutics?

Is SXTC or FHTX more profitable?

Do insiders & institutionals have more ownership in SXTC or FHTX?

Which has higher valuation and earnings, SXTC or FHTX?

Does the media favor SXTC or FHTX?

Do analysts prefer SXTC or FHTX?

Which has more risk and volatility, SXTC or FHTX?

Summary

How does China SXT Pharmaceuticals compare to Coeptis Therapeutics?

Do insiders and institutionals believe in SXTC or ZSQR?

Which has preferable valuation and earnings, SXTC or ZSQR?

Does the media favor SXTC or ZSQR?

Which has more risk & volatility, SXTC or ZSQR?

Do analysts prefer SXTC or ZSQR?

Is SXTC or ZSQR more profitable?

Summary

How does China SXT Pharmaceuticals compare to Editas Medicine?

Do analysts rate SXTC or EDIT?

Is SXTC or EDIT more profitable?

Which has more volatility and risk, SXTC or EDIT?

Do insiders & institutionals believe in SXTC or EDIT?

Which has better valuation and earnings, SXTC or EDIT?

Does the media refer more to SXTC or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC vs. The Competition

China SXT Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools